Dr. Shadi Nahvi is Professor (with tenure) in the Departments of Medicine and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine, and directs the General Internal Medicine and Addiction Medicine Fellowship Programs. Her research focuses on optimizing quality of life and health outcomes among persons with substance use disorder.
Dr. Nahvi’s research is grounded in nearly two decades of clinical experience as a primary care physician caring for persons with opioid and other substance use disorders. Her primary research focus is optimizing the efficacy and delivery of tobacco cessation treatments among persons with co-occurring substance use disorders. Currently, she is Principal Investigator of a NIDA R01-funded randomized, 2 x 2 factorial trial of directly observed and long-term varenicline treatment among smokers with opioid use disorder. She has also led a KL2 Career Development Award-funded, randomized, placebo-controlled pilot trial of varenicline for smoking cessation among smokers with co-morbid substance use disorder, a study of health system-level interventions to increase documentation and treatment of tobacco use among substance use disorder counselors, and a randomized trial of the efficacy of directly observed varenicline provided at a methadone clinic for promoting smoking cessation and enhancing adherence.
Dr. Nahvi graduated from the Brown University School of Medicine in 2001 and completed residency training in Primary Care Internal Medicine at Bellevue Hospital and New York University Medical Center in 2004. She then joined the faculty in the Albert Einstein College of Medicine Division of Substance Abuse as the Medical Director of an opioid treatment program. From 2006-2008, Dr. Nahvi completed a faculty fellowship supported by the Bronx Center to Reduce and Eliminate Ethnic and Racial Health Disparities and received a MS in Clinical Research Methods.
Dr. Nahvi has served on numerous national advisory committees, including serving as a member of the Advisory Committee of the Society for Research on Nicotine and Tobacco Health Disparities Network, and co-chair of the Evaluation Committee of the Health Disparities Network; a member of the NY State Department of Health AIDS Institute’s Guideline Committee for the Care of Substance Users; and a Steering Committee member of the NY State Department of Health AIDS Institute's Tobacco Cessation Improvement Campaign.
- Explain the burden of tobacco use among people with opioid use disorder
- Describe the importance of treating tobacco use among people with opioid use disorder
- Describe two treatments and health system strategies to address tobacco use among people with opioid use disorder
CME/CE credit is no longer available for this live activity. Credit will be offered again for the recorded version of this webinar by June.
Certificates of Attendance
Click here to generate a certificate of attendance for participating on this webinar.
ACCME Accreditation
In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
UCSF designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.
Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.
Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.
California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA category 1 CreditTM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.
California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditTM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.
California Behavioral Science Professionals: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.
Course meets the qualifications for 1.0 hour of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences. Provider # 64239.
ACCREDITATION FOR CALIFORNIA ADDICTION COUNSELORS
The UCSF office of continuing medical education is accredited by the California Consortium of Addiction Programs and Professionals (CCAPP), to provide continuing education credit for California addiction counselors. UCSF designates this live, virtual activity, for a maximum of 1.0 CCAPP credit. Addiction counselors should claim only the credit commensurate with the extent of their participation in the activity. Provider number: 7-20-322-0724.
Disclosures
This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Catherine Bonniot, Christine Cheng, Brian Clark, Jennifer Matekuare, Shadi Nahvi, MD, MS, Ma Krisanta Pamatmat, MPH, CHES, Jessica Safier, MA, and Maya Vijayaraghavan, MD, MAS
- To join the clinical trial, discussed in the webinar go to:https://clinicaltrials.gov/study/NCT05722561?term=el%20shahawy&rank=1 Caveat: Part of the eligibility criteria is getting treatment for OUD in the NYU, Bellevue or Montefiore system
- Another trial that will start soon: https://clinicaltrials.gov/study/NCT05881304?term=joanna%20streck&checkSpell=false&rank=1